Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 142

1.

Type 1 IGF receptor associates with adverse outcome and cellular radioresistance in paediatric high-grade glioma.

Simpson AD, Soo YWJ, Rieunier G, Aleksic T, Ansorge O, Jones C, Macaulay VM.

Br J Cancer. 2019 Dec 20. doi: 10.1038/s41416-019-0677-1. [Epub ahead of print]

PMID:
31857716
2.

Dual-specificity protein phosphatase DUSP4 regulates response to MEK inhibition in BRAF wild-type melanoma.

Gupta A, Towers C, Willenbrock F, Brant R, Hodgson DR, Sharpe A, Smith P, Cutts A, Schuh A, Asher R, Myers K, Love S, Collins L, Wise A, Middleton MR, Macaulay VM.

Br J Cancer. 2019 Dec 16. doi: 10.1038/s41416-019-0673-5. [Epub ahead of print]

PMID:
31839677
3.

Radioresistant laryngeal cancers upregulate type 1 IGF receptor and exhibit increased cellular dependence on IGF and EGF signalling.

Qureishi A, Rieunier G, Shah KA, Aleksic T, Winter SC, Møller H, Macaulay VM.

Clin Otolaryngol. 2019 Nov;44(6):1026-1036. doi: 10.1111/coa.13434. Epub 2019 Oct 4.

PMID:
31536667
4.

Therapeutic Targeting of the IGF Axis.

Osher E, Macaulay VM.

Cells. 2019 Aug 14;8(8). pii: E895. doi: 10.3390/cells8080895. Review.

5.

Increased EZH2 expression in prostate cancer is associated with metastatic recurrence following external beam radiotherapy.

Wu X, Scott H, Carlsson SV, Sjoberg DD, Cerundolo L, Lilja H, Prevo R, Rieunier G, Macaulay V, Higgins GS, Verrill CL, Lamb AD, Cunliffe VT, Bountra C, Hamdy FC, Bryant RJ.

Prostate. 2019 Jul;79(10):1079-1089. doi: 10.1002/pros.23817. Epub 2019 May 18.

6.

Rectifying long-standing misconceptions about the ρ statistic for molecular dating.

Macaulay V, Soares P, Richards MB.

PLoS One. 2019 Feb 19;14(2):e0212311. doi: 10.1371/journal.pone.0212311. eCollection 2019.

7.

Bad to the Bone: The Role of the Insulin-Like Growth Factor Axis in Osseous Metastasis.

Rieunier G, Wu X, Macaulay VM, Lee AV, Weyer-Czernilofsky U, Bogenrieder T.

Clin Cancer Res. 2019 Jun 15;25(12):3479-3485. doi: 10.1158/1078-0432.CCR-18-2697. Epub 2019 Feb 11. Review.

PMID:
30745299
8.

Nuclear IGF1R Interacts with Regulatory Regions of Chromatin to Promote RNA Polymerase II Recruitment and Gene Expression Associated with Advanced Tumor Stage.

Aleksic T, Gray N, Wu X, Rieunier G, Osher E, Mills J, Verrill C, Bryant RJ, Han C, Hutchinson K, Lambert AG, Kumar R, Hamdy FC, Weyer-Czernilofsky U, Sanderson MP, Bogenrieder T, Taylor S, Macaulay VM.

Cancer Res. 2018 Jul 1;78(13):3497-3509. doi: 10.1158/0008-5472.CAN-17-3498. Epub 2018 May 7.

9.

RAPTOR up-regulation contributes to resistance of renal cancer cells to PI3K-mTOR inhibition.

Earwaker P, Anderson C, Willenbrock F, Harris AL, Protheroe AS, Macaulay VM.

PLoS One. 2018 Feb 1;13(2):e0191890. doi: 10.1371/journal.pone.0191890. eCollection 2018.

10.

IGF-1R associates with adverse outcomes after radical radiotherapy for prostate cancer.

Aleksic T, Verrill C, Bryant RJ, Han C, Worrall AR, Brureau L, Larré S, Higgins GS, Fazal F, Sabbagh A, Haider S, Buffa FM, Cole D, Macaulay VM.

Br J Cancer. 2017 Nov 21;117(11):1600-1606. doi: 10.1038/bjc.2017.337. Epub 2017 Oct 3.

11.

Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination Studies.

Simpson A, Petnga W, Macaulay VM, Weyer-Czernilofsky U, Bogenrieder T.

Target Oncol. 2017 Oct;12(5):571-597. doi: 10.1007/s11523-017-0514-5. Review.

12.

TOPK modulates tumour-specific radiosensitivity and correlates with recurrence after prostate radiotherapy.

Pirovano G, Ashton TM, Herbert KJ, Bryant RJ, Verrill CL, Cerundolo L, Buffa FM, Prevo R, Harrap I, Ryan AJ, Macaulay V, McKenna WG, Higgins GS.

Br J Cancer. 2017 Aug 8;117(4):503-512. doi: 10.1038/bjc.2017.197. Epub 2017 Jul 4.

13.

Synthesis and bioactivity of fused- and spiro-β-lactone-lactam systems.

Josa-Culleré L, Towers C, Willenbrock F, Macaulay VM, Christensen KE, Moloney MG.

Org Biomol Chem. 2017 Jun 27;15(25):5373-5379. doi: 10.1039/c7ob01148b.

PMID:
28617490
14.

Mitogenome Diversity in Sardinians: A Genetic Window onto an Island's Past.

Olivieri A, Sidore C, Achilli A, Angius A, Posth C, Furtwängler A, Brandini S, Capodiferro MR, Gandini F, Zoledziewska M, Pitzalis M, Maschio A, Busonero F, Lai L, Skeates R, Gradoli MG, Beckett J, Marongiu M, Mazzarello V, Marongiu P, Rubino S, Rito T, Macaulay V, Semino O, Pala M, Abecasis GR, Schlessinger D, Conde-Sousa E, Soares P, Richards MB, Cucca F, Torroni A.

Mol Biol Evol. 2017 May 1;34(5):1230-1239. doi: 10.1093/molbev/msx082.

15.

Durable Response of Spinal Chordoma to Combined Inhibition of IGF-1R and EGFR.

Aleksic T, Browning L, Woodward M, Phillips R, Page S, Henderson S, Athanasou N, Ansorge O, Whitwell D, Pratap S, Hassan AB, Middleton MR, Macaulay VM.

Front Oncol. 2016 May 2;6:98. doi: 10.3389/fonc.2016.00098. eCollection 2016.

16.

Phase I Dose-Escalation Study of Linsitinib (OSI-906) and Erlotinib in Patients with Advanced Solid Tumors.

Macaulay VM, Middleton MR, Eckhardt SG, Rudin CM, Juergens RA, Gedrich R, Gogov S, McCarthy S, Poondru S, Stephens AW, Gadgeel SM.

Clin Cancer Res. 2016 Jun 15;22(12):2897-907. doi: 10.1158/1078-0432.CCR-15-2218. Epub 2016 Feb 1.

17.

Resolving the ancestry of Austronesian-speaking populations.

Soares PA, Trejaut JA, Rito T, Cavadas B, Hill C, Eng KK, Mormina M, Brandão A, Fraser RM, Wang TY, Loo JH, Snell C, Ko TM, Amorim A, Pala M, Macaulay V, Bulbeck D, Wilson JF, Gusmão L, Pereira L, Oppenheimer S, Lin M, Richards MB.

Hum Genet. 2016 Mar;135(3):309-26. doi: 10.1007/s00439-015-1620-z. Epub 2016 Jan 18.

18.

Inhibiting WEE1 Selectively Kills Histone H3K36me3-Deficient Cancers by dNTP Starvation.

Pfister SX, Markkanen E, Jiang Y, Sarkar S, Woodcock M, Orlando G, Mavrommati I, Pai CC, Zalmas LP, Drobnitzky N, Dianov GL, Verrill C, Macaulay VM, Ying S, La Thangue NB, D'Angiolella V, Ryan AJ, Humphrey TC.

Cancer Cell. 2015 Nov 9;28(5):557-568. doi: 10.1016/j.ccell.2015.09.015.

19.

IGF-1R inhibition induces schedule-dependent sensitization of human melanoma to temozolomide.

Ramcharan R, Aleksic T, Kamdoum WP, Gao S, Pfister SX, Tanner J, Bridges E, Asher R, Watson AJ, Margison GP, Woodcock M, Repapi E, Li JL, Middleton MR, Macaulay VM.

Oncotarget. 2015 Nov 24;6(37):39877-90. doi: 10.18632/oncotarget.5631.

20.

IGF-1R expression is associated with HPV-negative status and adverse survival in head and neck squamous cell cancer.

Dale OT, Aleksic T, Shah KA, Han C, Mehanna H, Rapozo DC, Sheard JD, Goodyear P, Upile NS, Robinson M, Jones TM, Winter S, Macaulay VM.

Carcinogenesis. 2015 Jun;36(6):648-55. doi: 10.1093/carcin/bgv053. Epub 2015 Apr 20.

PMID:
25896444
21.

Suppression of homologous recombination sensitizes human tumor cells to IGF-1R inhibition.

Lodhia KA, Gao S, Aleksic T, Esashi F, Macaulay VM.

Int J Cancer. 2015 Jun 15;136(12):2961-6. doi: 10.1002/ijc.29327. Epub 2014 Nov 25.

22.

Dsh homolog DVL3 mediates resistance to IGFIR inhibition by regulating IGF-RAS signaling.

Gao S, Bajrami I, Verrill C, Kigozi A, Ouaret D, Aleksic T, Asher R, Han C, Allen P, Bailey D, Feller S, Kashima T, Athanasou N, Blay JY, Schmitz S, Machiels JP, Upile N, Jones TM, Thalmann G, Ashraf SQ, Wilding JL, Bodmer WF, Middleton MR, Ashworth A, Lord CJ, Macaulay VM.

Cancer Res. 2014 Oct 15;74(20):5866-77. doi: 10.1158/0008-5472.CAN-14-0806. Epub 2014 Aug 28.

23.

Can we unlock the potential of IGF-1R inhibition in cancer therapy?

King H, Aleksic T, Haluska P, Macaulay VM.

Cancer Treat Rev. 2014 Oct;40(9):1096-105. doi: 10.1016/j.ctrv.2014.07.004. Epub 2014 Aug 4. Review.

24.

IGF-1R inhibition enhances radiosensitivity and delays double-strand break repair by both non-homologous end-joining and homologous recombination.

Chitnis MM, Lodhia KA, Aleksic T, Gao S, Protheroe AS, Macaulay VM.

Oncogene. 2014 Nov 6;33(45):5262-73. doi: 10.1038/onc.2013.460. Epub 2013 Nov 4.

25.

A substantial prehistoric European ancestry amongst Ashkenazi maternal lineages.

Costa MD, Pereira JB, Pala M, Fernandes V, Olivieri A, Achilli A, Perego UA, Rychkov S, Naumova O, Hatina J, Woodward SR, Eng KK, Macaulay V, Carr M, Soares P, Pereira L, Richards MB.

Nat Commun. 2013;4:2543. doi: 10.1038/ncomms3543.

26.

Evaluating purifying selection in the mitochondrial DNA of various mammalian species.

Soares P, Abrantes D, Rito T, Thomson N, Radivojac P, Li B, Macaulay V, Samuels DC, Pereira L.

PLoS One. 2013;8(3):e58993. doi: 10.1371/journal.pone.0058993. Epub 2013 Mar 22.

27.

Fatal case of sorafenib-associated idiosyncratic hepatotoxicity in the adjuvant treatment of a patient with renal cell carcinoma.

Fairfax BP, Pratap S, Roberts IS, Collier J, Kaplan R, Meade AM, Ritchie AW, Eisen T, Macaulay VM, Protheroe A.

BMC Cancer. 2012 Dec 11;12:590. doi: 10.1186/1471-2407-12-590.

28.

Phase I study of humanized monoclonal antibody AVE1642 directed against the type 1 insulin-like growth factor receptor (IGF-1R), administered in combination with anticancer therapies to patients with advanced solid tumors.

Macaulay VM, Middleton MR, Protheroe AS, Tolcher A, Dieras V, Sessa C, Bahleda R, Blay JY, LoRusso P, Mery-Mignard D, Soria JC.

Ann Oncol. 2013 Mar;24(3):784-91. doi: 10.1093/annonc/mds511. Epub 2012 Oct 26.

29.

Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin (AMVAC) as neoadjuvant chemotherapy for patients with muscle-invasive transitional cell carcinoma of the bladder.

Blick C, Hall P, Pwint T, Al-Terkait F, Crew J, Powles T, Macaulay V, Munro N, Douglas D, Kilbey N, Protheroe A, Chester JD.

Cancer. 2012 Aug 15;118(16):3920-7. doi: 10.1002/cncr.26675. Epub 2012 Jan 3.

30.

Mitochondrial DNA signals of late glacial recolonization of Europe from near eastern refugia.

Pala M, Olivieri A, Achilli A, Accetturo M, Metspalu E, Reidla M, Tamm E, Karmin M, Reisberg T, Hooshiar Kashani B, Perego UA, Carossa V, Gandini F, Pereira JB, Soares P, Angerhofer N, Rychkov S, Al-Zahery N, Carelli V, Sanati MH, Houshmand M, Hatina J, Macaulay V, Pereira L, Woodward SR, Davies W, Gamble C, Baird D, Semino O, Villems R, Torroni A, Richards MB.

Am J Hum Genet. 2012 May 4;90(5):915-24. doi: 10.1016/j.ajhg.2012.04.003.

31.

Depletion of the type 1 IGF receptor delays repair of radiation-induced DNA double strand breaks.

Turney BW, Kerr M, Chitnis MM, Lodhia K, Wang Y, Riedemann J, Rochester M, Protheroe AS, Brewster SF, Macaulay VM.

Radiother Oncol. 2012 Jun;103(3):402-9. doi: 10.1016/j.radonc.2012.03.009. Epub 2012 Apr 30.

PMID:
22551565
32.

Interdisciplinary approach to the demography of Jamaica.

Deason ML, Salas A, Newman SP, Macaulay VA, St A Morrison EY, Pitsiladis YP.

BMC Evol Biol. 2012 Feb 23;12:24. doi: 10.1186/1471-2148-12-24.

33.

The Expansion of mtDNA Haplogroup L3 within and out of Africa.

Soares P, Alshamali F, Pereira JB, Fernandes V, Silva NM, Afonso C, Costa MD, Musilová E, Macaulay V, Richards MB, Cerny V, Pereira L.

Mol Biol Evol. 2012 Mar;29(3):915-27. doi: 10.1093/molbev/msr245. Epub 2011 Nov 16.

PMID:
22096215
34.

Aberrant succination of proteins in fumarate hydratase-deficient mice and HLRCC patients is a robust biomarker of mutation status.

Bardella C, El-Bahrawy M, Frizzell N, Adam J, Ternette N, Hatipoglu E, Howarth K, O'Flaherty L, Roberts I, Turner G, Taylor J, Giaslakiotis K, Macaulay VM, Harris AL, Chandra A, Lehtonen HJ, Launonen V, Aaltonen LA, Pugh CW, Mihai R, Trudgian D, Kessler B, Baynes JW, Ratcliffe PJ, Tomlinson IP, Pollard PJ.

J Pathol. 2011 Sep;225(1):4-11. doi: 10.1002/path.2932. Epub 2011 Jun 1.

PMID:
21630274
35.

Importance of mitochondrial haplotypes and maternal lineage in sprint performance among individuals of West African ancestry.

Deason M, Scott R, Irwin L, Macaulay V, Fuku N, Tanaka M, Irving R, Charlton V, Morrison E, Austin K, Pitsiladis YP.

Scand J Med Sci Sports. 2012 Apr;22(2):217-23. doi: 10.1111/j.1600-0838.2010.01289.x. Epub 2011 Mar 16.

PMID:
21410543
36.

Ancient voyaging and Polynesian origins.

Soares P, Rito T, Trejaut J, Mormina M, Hill C, Tinkler-Hundal E, Braid M, Clarke DJ, Loo JH, Thomson N, Denham T, Donohue M, Macaulay V, Lin M, Oppenheimer S, Richards MB.

Am J Hum Genet. 2011 Feb 11;88(2):239-47. doi: 10.1016/j.ajhg.2011.01.009. Epub 2011 Feb 3.

37.

Population expansion in the North African late Pleistocene signalled by mitochondrial DNA haplogroup U6.

Pereira L, Silva NM, Franco-Duarte R, Fernandes V, Pereira JB, Costa MD, Martins H, Soares P, Behar DM, Richards MB, Macaulay V.

BMC Evol Biol. 2010 Dec 21;10:390. doi: 10.1186/1471-2148-10-390.

38.

Serial analysis of resected prostate cancer suggests up-regulation of type 1 IGF receptor with disease progression.

Turney BW, Turner GD, Brewster SF, Macaulay VM.

BJU Int. 2011 May;107(9):1488-99. doi: 10.1111/j.1464-410X.2010.09556.x. Epub 2010 Sep 14.

39.

Type 1 insulin-like growth factor receptor translocates to the nucleus of human tumor cells.

Aleksic T, Chitnis MM, Perestenko OV, Gao S, Thomas PH, Turner GD, Protheroe AS, Howarth M, Macaulay VM.

Cancer Res. 2010 Aug 15;70(16):6412-9. doi: 10.1158/0008-5472.CAN-10-0052.

40.

About the X-to-Y gene conversion rate.

Cruciani F, Trombetta B, Macaulay V, Scozzari R.

Am J Hum Genet. 2010 Mar 12;86(3):495-7; author reply 497-8. doi: 10.1016/j.ajhg.2010.01.033. No abstract available.

41.

Silencing of the insulin receptor isoform A favors formation of type 1 insulin-like growth factor receptor (IGF-IR) homodimers and enhances ligand-induced IGF-IR activation and viability of human colon carcinoma cells.

Brierley GV, Macaulay SL, Forbes BE, Wallace JC, Cosgrove LJ, Macaulay VM.

Endocrinology. 2010 Apr;151(4):1418-27. doi: 10.1210/en.2009-1006. Epub 2010 Feb 23.

PMID:
20179263
42.

The archaeogenetics of Europe.

Soares P, Achilli A, Semino O, Davies W, Macaulay V, Bandelt HJ, Torroni A, Richards MB.

Curr Biol. 2010 Feb 23;20(4):R174-83. doi: 10.1016/j.cub.2009.11.054. Review.

43.

An adult Xp11.2 translocation renal carcinoma showing response to treatment with sunitinib.

Pwint TP, Macaulay V, Roberts IS, Sullivan M, Protheroe A.

Urol Oncol. 2011 Nov-Dec;29(6):821-4. doi: 10.1016/j.urolonc.2009.10.007. Epub 2009 Dec 4.

PMID:
19962921
44.

Information for genetic management of mtDNA disease: sampling pathogenic mtDNA mutants in the human germline and in placenta.

Marchington D, Malik S, Banerjee A, Turner K, Samuels D, Macaulay V, Oakeshott P, Fratter C, Kennedy S, Poulton J.

J Med Genet. 2010 Apr;47(4):257-61. doi: 10.1136/jmg.2009.072900. Epub 2009 Nov 12.

PMID:
19914907
45.

Mitochondrial echoes of first settlement and genetic continuity in El Salvador.

Salas A, Lovo-Gómez J, Alvarez-Iglesias V, Cerezo M, Lareu MV, Macaulay V, Richards MB, Carracedo A.

PLoS One. 2009 Sep 2;4(9):e6882. doi: 10.1371/journal.pone.0006882.

46.

Validation of the type 1 insulin-like growth factor receptor as a therapeutic target in renal cancer.

Yuen JS, Akkaya E, Wang Y, Takiguchi M, Peak S, Sullivan M, Protheroe AS, Macaulay VM.

Mol Cancer Ther. 2009 Jun;8(6):1448-59. doi: 10.1158/1535-7163.MCT-09-0101. Epub 2009 Jun 9.

47.

Correcting for purifying selection: an improved human mitochondrial molecular clock.

Soares P, Ermini L, Thomson N, Mormina M, Rito T, Röhl A, Salas A, Oppenheimer S, Macaulay V, Richards MB.

Am J Hum Genet. 2009 Jun;84(6):740-59. doi: 10.1016/j.ajhg.2009.05.001. Epub 2009 Jun 4.

48.

The diversity present in 5140 human mitochondrial genomes.

Pereira L, Freitas F, Fernandes V, Pereira JB, Costa MD, Costa S, Máximo V, Macaulay V, Rocha R, Samuels DC.

Am J Hum Genet. 2009 May;84(5):628-40. doi: 10.1016/j.ajhg.2009.04.013. Epub 2009 May 7.

49.

The type 1 insulin-like growth factor receptor pathway.

Chitnis MM, Yuen JS, Protheroe AS, Pollak M, Macaulay VM.

Clin Cancer Res. 2008 Oct 15;14(20):6364-70. doi: 10.1158/1078-0432.CCR-07-4879. Review.

50.

Targeting the type 1 insulin-like growth factor receptor as a treatment for cancer.

Yuen JS, Macaulay VM.

Expert Opin Ther Targets. 2008 May;12(5):589-603. doi: 10.1517/14728222.12.5.589 . Review.

PMID:
18410242

Supplemental Content

Loading ...
Support Center